Metra Biosystems
This article was originally published in The Gray Sheet
Executive Summary
Raises additional $5.1 mil. of equity financing, bringing the total raised during its third round of financing to $12.1 mil. In January, the firm had announced an initial closing of the round at $7 mil. ("The Gray Sheet" Feb. 7, p. 24). New investors include The Traveler's Companies, New York Life, Spears Benzac Solomon & Farrell, Welch & Forbes, and "investors associated with BEA." The Palo Alto, California firm will use the funds for "continued development and commercialization of comprehensive tests for the identification and treatment of bone and cartilage diseases, including osteoporosis, osteoarthritis, hyperthyroidism, hyperparathyroidism, and Paget's disease"